Please ensure Javascript is enabled for purposes of website accessibility

Here's Why PTC Therapeutics Fell as Much as 12.5% Today

By Maxx Chatsko – Sep 18, 2019 at 12:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The business is raising cash through two offerings: one of debt and one of common stock.

What happened

Shares of PTC Therapeutics (PTCT 0.96%) fell more than 12% after the company announced the pricing of a debt offering and a share offering. The business will sell up to $287.5 million in debt notes and up to $115 million in common stock for total gross proceeds of up to $402.5 million.

The transactions will pad a balance sheet that sported $363 million in cash at the end of June. PTC Therapeutics can certainly use it. The business reported operating cash outflow of $73 million in the first six months of 2019. That's likely to increase in the near future as the company launches two new products in Latin America, prepares to submit another product to regulators for approval, and expands the use of an important drug product following a recent thumbs-up from regulators.

As of 12:22 p.m. EDT, the stock had settled to a 12.2% loss. The growth stock has gained 315% in the last three years.

A line chart on a chalkboard showing a steady rise and then a sudden fall.

Image source: Getty Images.

So what

PTC Therapeutics has two marketed products for treating Duchenne muscular dystrophy (DMD): Translarna and Emflaza. They generated $138 million in revenue in the first six months of 2019, compared to $124 million in the year-ago period. That slow growth could accelerate soon, as Emflaza recently received approval from the U.S. Food and Drug Administration (FDA) to treat DMD patients between 2 years and 5 years of age. Those patients represent approximately 25% of all individuals with the disease.

That said, the expanded label won't immediately shore up the company's financial position. PTC Therapeutics reported an operating loss of $247 million and an operating cash outflow of $73 million in the first half of 2019. Operating expenses are expected to rise significantly in the near future to support growth efforts.

PTC Therapeutics plans to submit a new drug application (NDA) to the FDA for risdiplam as a treatment for spinal muscular atrophy (SMA) type 1, type 2, and type 3. If the drug earns marketing approval, investors can expect marketing expenses to increase during launch. Similarly, the company is about to launch Tegsedi and Waylivra in Latin America and is expanding its research efforts in gene therapy, which is an inherently expensive area of medicine.

Now what

Today's stock move is pretty straightforward: Investors are simply adjusting the company's market cap to account for dilution from the stock offering. Of course, the business had to raise outside cash to continue funding operations and expansion. It's going to take more than a few quarters for PTC Therapeutics to achieve operating profits, but the company can now focus its bandwidth on execution instead of financing.

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

PTC Therapeutics, Inc. Stock Quote
PTC Therapeutics, Inc.
PTCT
$50.68 (0.96%) $0.48

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.